Recently, the generation of EBV specific T cell responses was shown to be dependent on this signalling pathway in a patient with EBV-driven recurrent lymphoproliferative disorder who had a CD70 deficiency [59] and stimulation of CD27 using agonist antibodies has been shown to enhance therapeutic vaccination in cancer immunotherapy [60]. This evidence concerns the gene CD27 and cancer.